Influenza in long-term care facilities: Preventable, detectable, treatable

Cleveland Clinic Journal of Medicine

Volumn 76, Issue 9, 2009, Pages 513-521

  Mossad, Sherif B ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE;

AGED; ANTIVIRAL RESISTANCE; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; LONG TERM CARE; NURSING HOME; REVIEW; UNITED STATES;

AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LONG-TERM CARE; NURSING HOMES; UNITED STATES;

EID: 70449702196     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.76a.09022     Document Type: Review

References (56)

1. Cifu A, Levinson W. Influenza. JAMA 2000; 284:2847-2849.
2. Sullivan KM. Health impact of influenza in the United States. Pharmacoeconomics 1996; 9(suppl 3):26-33.
3. Fiore AE, Shay DK, Broder K, et al; US Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57:1-60.
4. Sprenger MJ, Mulder PG, Beyer WE, Van Strik R, Masurel N. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. Int J Epidemiol 1993; 22:334-340.
5. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196:249-257.
6. Centers for Disease Control and Prevention (CDC). Update: Influenza activity-United States, September 28, 2008-January 31, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:115-119.
7. CDC issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008-09 influenza season. Distributed via Health Alert Network. 2008. www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00279. Accessed 7/14/2009.
8. Weinstock DM, Zuccotti G. The evolution of influenza resistance and treatment. JAMA 2009; 301:1066-1069.
9. Barker WH, Borisute H, Cox C. A study of the impact of influenza on the functional status of frail older people. Arch Intern Med 1998; 158:645-650.
10. Menec VH, MacWilliams L, Aoki FY. Hospitalization and deaths due to respiratory illnesses during influenza seasons: a comparison of community residents, senior housing residents, and nursing home residents. J Gerontol A Biol Sci Med Sci 2002; 57:M629-M635.
11. Kingston BJ, Wright CV Jr. Influenza in the nursing home. Am Fam Physician 2002; 65:75-78.
12. Whitley RJ, Monto AS. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis 2006; 194(suppl 2):S133-S138.
13. Monto AS, Rotthoff J, Teich E, et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis 2004; 39:459-464.
14. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366:1165-1174.
15. Rivetti D, Jefferson T, Thomas R, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006; 3:CD004876.
16. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7:658-666.
17. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005; 165:265-272.
18. Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in patients with pneumonia outside "flu" season: pleiotropic benefits or residual confounding? Am J Respir Crit Care Med 2008; 178:527-533.
19. Jackson ML, Nelson JC, Weiss NS, Neuzil KM, Barlow W, Jackson LA. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 2008; 372:398-405.
20. Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002; 35:370-377.
21. Voordouw AC, Sturkenboom MC, Dieleman JP, et al. Annual revacination against influenza and mortality risk in community-dwelling elderly persons. JAMA 2004; 292:2089-2095.
22. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-1127.
23. Keitel WA, Atmar RL, Nino D, Cate TR, Couch RB. Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. J Infect Dis 2008; 198:1016-1018.
24. Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med 2006; 166:1301-1304.
25. Sivadon-Tardy V, Orlikowski D, Porcher R, et al. Guillain-Barré syndrome and influenza virus infection. Clin Infect Dis 2009; 48:48-56.
26. Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 2008; 197:490-502.
27. Paccalin M, Plouzeau C, Bouche G, et al. Lack of correlation between nutritional status and seroprotection against influenza in a long term care facility. Scand J Infect Dis 2006; 38:894-897.
28. Mody L, Langa KM, Malani PN. Impact of the 2004-2005 influenza vaccine shortage on immunization practices in long-term care facilities. Infect Control Hosp Epidemiol 2006; 27:383-387.
29. Shefer A, McKibben L, Bardenheier B, Bratzler D, Roberts H. Characteristics of long-term care facilities associated with standing order programs to deliver influenza and pneumococcal vaccinations to residents in 13 states. J Am Med Dir Assoc 2005; 6:97-104.
30. Bardenheier BH, Shefer A, McKibben L, Roberts H, Rhew D, Bratzler D. Factors predictive of increased influenza and pneumococcal vaccination coverage in long-term care facilities: the CMS-CDC standing orders program project. J Am Med Dir Assoc 2005; 6:291-299.
31. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000; 355:93-97.
32. Hayward AC, Harling R, Wetten S, et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ 2006; 333:1241.
33. Thomas RE, Jefferson T, Demicheli V, Rivetti D. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev 2006; 3:CD005187.
34. Backer H. Counterpoint: in favor of mandatory influenza vaccine for all health care workers. Clin Infect Dis 2006; 42:1144-1147.
35. Finch M. Point: mandatory influenza vaccination for all health care workers? Seven reasons to say "no". Clin Infect Dis 2006; 42:1141-1143.
36. Bertin M, Scarpelli M, Proctor AW, et al. Novel use of the intranet to document health care personnel participation in a mandatory influenza vaccination reporting program. Am J Infect Control 2007; 35:33-37.
37. Jefferson T, Foxlee R, Del Mar C, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review. BMJ 2008; 336:77-80.
38. Pittet D, Allegranzi B, Sax H, et al; WHO Global Patient Safety Challenge, World Alliance for Patient Safety. Evidence-based model for hand transmission during patient care and the role of improved practices. Lancet Infect Dis 2006; 6:641-652.
39. Bischoff WE, Reynolds TM, Sessler CN, Edmond MB, Wenzel RP. Handwashing compliance by health care workers: the impact of introducing an accessible, alcohol-based hand antiseptic. Arch Intern Med 2000; 160:1017-1021.
40. US Centers for Disease Control and Prevention. Influenza-testing and antiviral-agent prescribing practices-Connecticut, Minnesota, New Mexico, and New York, 2006-07 influenza season. MMWR Morb Mortal Wkly Rep 2008; 57:61-65.
41. Harper SA, Bradley JS, Englund JA, et al; Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003-1032.
42. Drinka PJ, Krause PF, Nest LJ, Goodman BM, Gravenstein S. Risk of acquiring influenza B in a nursing home from a culture-positive roommate. J Am Geriatr Soc 2005; 53:1437.
43. Haber MJ, Shay DK, Davis XM, et al. Effectiveness of interventions to reduce contact rates during a simulated influenza pandemic. Emerg Infect Dis 2007; 13:581-589.
44. Keyser LA, Karl M, Nafziger AN, Bertino JS Jr. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med 2000; 160:1485-1488.
45. Saito R, Oshitani H, Masuda H, Suzuki H. Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs. J Clin Microbiol 2002; 40:84-88.
46. Peters PH Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49:1025-1031.
47. Bowles SK, Kennie N, Ruston L, Simor A, Louie M, Collins V. Influenza outbreak in a long-term-care facility: considerations for pharmacy. Am J Health Syst Pharm 1999; 56:2303-2307.
48. Risebrough NA, Bowles SK, Simor AE, McGeer A, Oh PI. Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities. J Am Geriatr Soc 2005; 53:444-451.
49. Ambrozaitis A, Gravenstein S, van Essen GA, et al. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. J Am Med Dir Assoc 2005; 6:367-374.
50. Gravenstein S, Drinka P, Osterweil D, et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. J Am Med Dir Assoc 2005; 6:359-366.
51. Diggory P, Fernandez C, Humphrey A, Jones V, Murphy M. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 2001; 322:577-579.
52. Glezen WP. Clinical practice: prevention and treatment of seasonal influenza. N Engl J Med 2008; 359:2579-2585.
53. Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001; 161:212-217.
54. Lin JT, Yu XZ, Cui DJ, et al. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. Curr Med Res Opin 2006; 22:75-82.
55. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009; 48(suppl 1):S3-S13.
56. Guo R, Pittler MH, Ernst E. Complementary medicine for treating or preventing influenza or influenza-like illness. Am J Med 2007; 120:923-929.